Patent ID: 9561291
Date: 2017-02-07
CPC Classifications: A61K

Claim:
1. A method of targeting human T-cells to human tumor cells in a human host, said method comprising: (a) administering to said host a first tumor specific antibody binding to human carcinoembryonic antigen (CEA), CD19 or CD20, wherein said first tumor specific antibody is conjugated to a first member of a pair of specific binding moieties, in an amount sufficient to bind to the tumor cells in said host; (b) administering to said host a clearing compound conjugated to the second member of said pair of specific binding moieties and allowing sufficient amount of time for the non-tumor bound fraction of said conjugated first antibody to be eliminated from said host; (c) administering to said host a second T-cell specific antibody binding to human CTLA-4, wherein said second T-cell antibody is conjugated to the second member of said pair of specific binding moieties, in an amount sufficient to bind to the T-cells of said host and not more than about 5 mg; and (d) allowing sufficient amount of time for said first and second members of said pair of specific binding moieties to bind to each other, thereby targeting said T-cells to said tumor cells, wherein said method reduces immune related adverse events (irAEs) in a patient being treated for cancer relative to administration of anti-CTLA-4 antibody alone without said targeting.